Market Overview:
The global COPD drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of COPD, rising awareness about COPD and its treatment options, and the launch of novel therapies. Based on type, the global COPD drugs market is segmented into bronchodilators, PDE-4 inhibitors, steroids, combination therapies, and others. Bronchodilators are further sub-segmented into short-acting bronchodilators and long-acting bronchodilators. Steroids are further sub-segmented into systemic steroids and inhaled steroids. Combination therapies are further sub-segmented into dual therapy and triple therapy combinations. Others include mucolytics agents (acetylcysteine), antibiotics (macrolides), phosphodiesterase type 4 inhibitors (roflumilast) etc., which have a limited share in this market currently but are expected to witness high growth rates during the forecast period owing to their growing use in various regions across the globe. Based on application, hospitals accounted for majority share of revenue generated by this market in 2017 while clinics held second largest share followed by other applications such as home care settings & respiratory rehabilitation centers etc.
Product Definition:
COPD Drugs are medications that are used to treat chronic obstructive pulmonary disease (COPD). COPD is a lung disease that causes airflow obstruction and makes it difficult to breathe. COPD Drugs help improve breathing and reduce the risk of exacerbations. They may also help improve quality of life for people with COPD.
Bronchodilators:
Bronchodilators are drugs that widen the airways and increase the rate of airflow in the lungs. The most common types of bronchodilators are beta-agonists, which include Albuterol (Ventolin), Prolong (Lopressor), and Metaproterenol (Rapid acting form).
PDE-4 Inhibitors:
PDE-4 inhibitors are a new class of drugs that prevent the breakdown of cyclic adenosine monophosphate (cAMP) by inhibiting the PDE-4 enzyme. The cAMP signal transduction pathway is used by lung cells to communicate with nearby cells and tissues. Blocking this pathway causes pulmonary vasodilatation, which results in decreased airway resistance and increased airflow.
Application Insights:
Based on the application, the global COPD drugs market is segmented into hospitals, clinics and other medical facilities, and others. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a large patient base with a high prevalence of COPD across various hospitals globally. Furthermore, an increase in healthcare spending due to growing geriatric population coupled with rising incidence rates of COPD will boost industry growth over the forecast period.
The clinic/others segment is expected to witness significant growth during the forecast period owing to increasing awareness about early diagnosis and treatment among patients which encourages them to seek medical consultation for any respiratory issue they experience along with their doctor's advice regarding available treatments options at clinics or outside hospital premises where consultations are free of charge unlike hospital-based ones where charges apply for each consultation room used.
Regional Analysis:
North America dominated the global COPD drugs market in 2017. The presence of key players, favorable reimbursement policies, and high healthcare expenditure are some of the factors responsible for its dominance. According to a study published in NCBI, in 2016 around USD X billion were spent on medication for COPD and related conditions such as asthma and emphysema across North America.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to various initiatives taken up by governments & private organizations that aim at increasing awareness regarding early diagnosis & treatment of chronic respiratory diseases such as asthma.
Growth Factors:
- Increasing prevalence of COPD: The global prevalence of COPD is expected to increase from approximately 210 million in 2015 to nearly 250 million by 2025. This is due to the aging population and rising smoking rates in developing countries.
- Growing demand for novel therapies: There is a growing demand for novel therapies that can improve patient outcomes and quality of life. This has led to the development of several new drugs, such as tiotropium bromide (Spiriva), umeclidinium bromide (Incruse Ellipta), and glycopyrronium bromide (Seebri Breezhaler).
- Launch of generic versions: Several blockbuster drugs for COPD are scheduled to lose patent protection in the next few years, leading to the launch of generic versions. For example, tiotropium bromide (Spiriva) will lose patent protection in 2020, while salmeterol xinafoate/fluticasone propionate (Advair Diskus) will lose patent protection in 2023. This will lead to increased competition and lower prices for these drugs.
Scope Of The Report
Report Attributes
Report Details
Report Title
COPD Drugs Market Research Report
By Type
Bronchodilators, PDE-4 Inhibitors, Steroids, Combination Therapies, Others
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Mylan NV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global COPD Drugs Market Report Segments:
The global COPD Drugs market is segmented on the basis of:
Types
Bronchodilators, PDE-4 Inhibitors, Steroids, Combination Therapies, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- GlaxoSmithKline
- Merck
- Abbott Laboratories
- Boehringer Ingelheim
- AstraZeneca
- Roche Holding AG
- Teva Pharmaceutical Industries
- Vectura Group
- Mylan NV
Highlights of The COPD Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bronchodilators
- PDE-4 Inhibitors
- Steroids
- Combination Therapies
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the COPD Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
COPD drugs are medications used to treat COPD, a lung disease. COPD includes chronic bronchitis and emphysema. COPD drugs can help improve airflow in the lungs and reduce inflammation in the airways.
Some of the major players in the copd drugs market are Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Mylan NV.
The copd drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 COPD Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 COPD Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 COPD Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the COPD Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global COPD Drugs Market Size & Forecast, 2020-2028
4.5.1 COPD Drugs Market Size and Y-o-Y Growth
4.5.2 COPD Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Bronchodilators
5.2.2 PDE-4 Inhibitors
5.2.3 Steroids
5.2.4 Combination Therapies
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global COPD Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 COPD Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Bronchodilators
9.6.2 PDE-4 Inhibitors
9.6.3 Steroids
9.6.4 Combination Therapies
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Bronchodilators
10.6.2 PDE-4 Inhibitors
10.6.3 Steroids
10.6.4 Combination Therapies
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Bronchodilators
11.6.2 PDE-4 Inhibitors
11.6.3 Steroids
11.6.4 Combination Therapies
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Bronchodilators
12.6.2 PDE-4 Inhibitors
12.6.3 Steroids
12.6.4 Combination Therapies
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Bronchodilators
13.6.2 PDE-4 Inhibitors
13.6.3 Steroids
13.6.4 Combination Therapies
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 COPD Drugs Market: Competitive Dashboard
14.2 Global COPD Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 GlaxoSmithKline
14.3.4 Merck
14.3.5 Abbott Laboratories
14.3.6 Boehringer Ingelheim
14.3.7 AstraZeneca
14.3.8 Roche Holding AG
14.3.9 Teva Pharmaceutical Industries
14.3.10 Vectura Group
14.3.11 Mylan NV
